BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Eurand (Milan, Italy) Files IPO Registration Statement with SEC


5/1/2007 8:53:27 AM

MILAN, Italy and DAYTON, Ohio, May 1 /PRNewswire/ -- Eurand, a global specialty pharmaceutical company, announced today that it has filed a Form F-1 Registration Statement with the Securities and Exchange Commission relating to the initial public offering of 7 million Ordinary Shares of Eurand. In addition, Warburg Pincus Equity Partners, L.P. and its affiliates, Warburg Pincus Ventures International, L.P. and Gearoid Faherty, Eurand's Chief Executive Officer, have granted the underwriters an option to purchase a maximum of 1,050,000 Ordinary Shares to cover over-allotments.

The Company has applied to list its Ordinary Shares on the Nasdaq Global Market under the symbol "EURX."

Deutsche Bank Securities Inc. and Lehman Brothers Inc. will act as joint bookrunners and representatives of the underwriters. Banc of America Securities LLC, Lazard Capital Markets LLC and Thomas Weisel Partners LLC will act as co-managers.

The offering of Ordinary Shares will be made pursuant to a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained by contacting the prospectus department at (a) Deutsche Bank Securities Inc. by telephone at 1-800-503-4611, by email at: prospectusrequest@list.db.com or by mail at: Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Jersey City, NJ 07311 or (b) Lehman Brothers Inc. by email at: qiana.smith@broadridge.com, by mail to: Lehman Brothers c/o Broadridge, 1155 Long Island Avenue, Edgewood, NY 11717 or by fax at 631-254-7268.

The Registration Statement relating to the proposed sale of these securities has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Eurand

Eurand is a global specialty pharmaceutical company with research and manufacturing facilities in Milan and Trieste, Italy; Dayton, Ohio, USA; Paris, France.

This release, and oral statements made with respect to information contained in this release, constitute forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to Eurand's intention to conduct an initial public offering of Eurand's Ordinary Shares. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Actual events could differ materially from those anticipated in the forward-looking statements as a result of certain factors, including but not limited to: adverse changes in general economic or market conditions, the inability to manage successfully and complete the initial public offering and the risk that the initial public offering of Eurand may not occur in its expected timeframe or at all.

Source: Eurand Inc.

>>> Discuss This Story



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES